Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing Klebsiella pneumoniae

The Annals of Pharmacotherapy
Ola MashniJennifer Le

Abstract

To review the clinical data on the effectiveness and safety of double carbapenem therapy (DCT) in patients infected with carbapenemase-producing Klebsiella pneumoniae (CP-Kp). A literature search was performed utilizing PubMed and EMBASE (from 1966 to May 2018); bibliographies of the retrieved articles were also searched. Articles were included if they evaluated patients with infections caused by CP-Kp and were treated with DCT. Meeting abstracts, editorials, and animal and in vitro studies were excluded. The search strategy revealed 8 case reports and 6 clinical studies (total of 171 patients) that evaluated the administration of ertapenem followed by prolonged infusions of meropenem or doripenem. Most patients were critically ill and commonly had infections in the blood, lungs, and urine. Clinical and microbiological success were reported in 70% of the patients and mortality in 24%. Adverse events, which included mostly seizures, sodium disorders, and gastrointestinal symptoms, were reported in 16 patients; none required interruption of treatment. Relevance to Patient Care and Clinical Practice: This review evaluated the clinical experience of DCT in the treatment of CP-Kp infections, based on case reports and clinical studie...Continue Reading

References

Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Thierry NaasClaire Poyart
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Maria Virginia VillegasUNKNOWN Colombian Nosocomial Resistance Study Group
Mar 28, 2009·The Lancet Infectious Diseases·Patrice NordmannThierry Naas
Aug 29, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Abraham BorerMichael Sherf
Mar 23, 2011·Antimicrobial Agents and Chemotherapy·Catharine C Bulik, David P Nicolau
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Feb 1, 2012·Antimicrobial Agents and Chemotherapy·Martin HoeniglAndrea J Grisold
Dec 14, 2012·Annals of Clinical Microbiology and Antimicrobials·Grace C Lee, David S Burgess
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Ilias Karaiskos, Helen Giamarellou
Jun 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L S TzouvelekisG L Daikos
Jul 19, 2014·Journal of Psychiatric Practice·David McMahon, Sheldon H Preskorn
Oct 12, 2014·The Journal of Infection·Nathalie Grace ChuaAndrea L Kwa
Jan 20, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Alessandra OlivaVincenzo Vullo
Apr 23, 2015·The Journal of Antimicrobial Chemotherapy·Mario TumbarelloUNKNOWN ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva)
Sep 20, 2015·Antimicrobial Agents and Chemotherapy·Jose F CamargoRafael Cantón
Sep 27, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A OlivaV Vullo
Sep 30, 2015·The Journal of Antimicrobial Chemotherapy·Laurent PoirelPatrice Nordmann
Nov 11, 2015·Antimicrobial Agents and Chemotherapy·Jessica B Cprek, Jason C Gallagher
Mar 15, 2016·American Journal of Respiratory and Critical Care Medicine·Jason A RobertsJeffrey Lipman
Apr 22, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David van Duin, Robert A Bonomo
Sep 15, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ryan K ShieldsM Hong Nguyen
Feb 18, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M SouliH Giamarellou
Jul 7, 2017·Critical Care : the Official Journal of the Critical Care Forum·Gennaro De PascaleMassimo Antonelli
Jul 15, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nuria Piedra-CarrascoJuan José González-López
Apr 21, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Young R Lee, Nathaniel T Baker

❮ Previous
Next ❯

Citations

Dec 18, 2019·Antimicrobial Agents and Chemotherapy·David Aguilera-AlonsoFernando Baquero-Artigao
Dec 10, 2019·Current Opinion in Infectious Diseases·Juliette Patrier, Jean-François Timsit
Nov 16, 2019·The Journal of Antimicrobial Chemotherapy·Alexander LawandiTodd C Lee
Mar 17, 2020·Journal of Anaesthesiology, Clinical Pharmacology·Sai SaranAfzal Azim
Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
Apr 29, 2021·Journal of the American Chemical Society·Chi-Wang MaDan Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Nuria Piedra-CarrascoJuan José González-López
The Annals of Pharmacotherapy
Melanie K ClabornBrooke L Gildon
© 2022 Meta ULC. All rights reserved